Chemours (NYSE:CC) Given New $13.00 Price Target at Barclays

Chemours (NYSE:CC - Free Report) had its price objective decreased by Barclays from $16.00 to $13.00 in a research note released on Wednesday morning,Benzinga reports. Barclays currently has an equal weight rating on the specialty chemicals company's stock.

Other research analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Chemours from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Morgan Stanley reduced their price target on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th. Truist Financial reduced their price target on shares of Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Mizuho set a $15.00 price target on shares of Chemours in a research report on Tuesday, April 15th. Finally, Royal Bank of Canada reduced their price target on shares of Chemours from $17.00 to $14.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $17.22.

Chemours Stock Up 0.4%

NYSE CC traded up $0.04 during trading hours on Wednesday, reaching $10.15. 5,382,386 shares of the company traded hands, compared to its average volume of 2,142,803. Chemours has a 12 month low of $9.33 and a 12 month high of $25.80. The company has a current ratio of 1.68, a quick ratio of 0.92 and a debt-to-equity ratio of 6.70. The stock has a market capitalization of $1.52 billion, a PE ratio of 17.81 and a beta of 1.76. The company has a 50 day moving average of $11.63 and a two-hundred day moving average of $15.74.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). Chemours had a net margin of 1.51% and a return on equity of 26.54%. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter last year, the company earned $0.32 earnings per share. The company's revenue was up .4% compared to the same quarter last year. As a group, equities analysts expect that Chemours will post 2.03 earnings per share for the current year.

Chemours Announces Dividend

The company also recently disclosed a dividend, which will be paid on Monday, June 16th. Investors of record on Monday, May 19th will be issued a $0.0875 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a dividend yield of 3.17%. Chemours's dividend payout ratio (DPR) is presently 175.00%.

Insider Buying and Selling

In other news, CFO Shane Hostetter acquired 4,450 shares of the company's stock in a transaction that occurred on Monday, May 19th. The shares were acquired at an average price of $11.28 per share, with a total value of $50,196.00. Following the acquisition, the chief financial officer now directly owns 59,694 shares in the company, valued at approximately $673,348.32. The trade was a 8.06% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.34% of the company's stock.

Institutional Trading of Chemours

A number of large investors have recently modified their holdings of the company. FNY Investment Advisers LLC acquired a new position in Chemours during the 1st quarter valued at about $27,000. UMB Bank n.a. increased its stake in Chemours by 73.9% during the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock valued at $30,000 after buying an additional 948 shares during the period. Farther Finance Advisors LLC increased its stake in Chemours by 170.7% during the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after buying an additional 1,444 shares during the period. SouthState Corp acquired a new position in Chemours during the 1st quarter valued at about $34,000. Finally, Quadrant Capital Group LLC increased its stake in Chemours by 100.4% during the 4th quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock valued at $38,000 after buying an additional 1,119 shares during the period. Institutional investors and hedge funds own 76.26% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.